XPOVIO is the world’s first approved orally available selective inhibitor of the nuclear export protein XPO1. Credit: Nemes Laszlo / Shutterstock.com.

Antengene has signed a collaboration agreement with Hansoh Pharmaceutical Group (Hansoh Pharma) to commercialise XPOVIO (selinexor) in Mainland China.

XPOVIO is the world’s first approved orally available selective inhibitor of the nuclear export protein XPO1.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

XPOVIO secured its approval for use in mainland China along with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.

It is intended for patients who have previously received therapies, as well as those whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent and an anti-CD38 monoclonal antibody.

Antengene founder, chairman and CEO Dr Jay Mei stated: “Through collaborating with Hansoh Pharma, we will leverage their well-established commercialisation infrastructure to make XPOVIO more accessible to patients in mainland China.”

See Also:

Antengene will continue XPOVIO’s activities related to research, development, regulatory approvals, product supply and distribution.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hansoh Pharma will exclusively manage the commercialisation of XPOVIO in mainland China.

Antengene is eligible for 200m yuan ($27.7m) in upfront payments from Hansoh Pharma, with 100m yuan due upon the signing of the agreement.

The company could also secure milestone payments of up to 535m yuan from Hansoh Pharma.

Hansoh executive director Yuan Sun stated: “We look forward to collaborating with Antengene and making XPOVIO available to the widest possible number of Chinese patients with haematological malignancies.”